Fig. 6: GRP78-CAR T cells have potent anti-AML activity in vivo. | Nature Communications

Fig. 6: GRP78-CAR T cells have potent anti-AML activity in vivo.

From: CAR T cells redirected to cell surface GRP78 display robust anti-acute myeloid leukemia activity and do not target hematopoietic progenitor cells

Fig. 6

a Schematic of the in vivo experimental design. b NSG mice were injected with MOLM13 (5 × 103) cells i.v. (tail vein), and on day 7 received a single i.v. dose of 1 × 107 T cells. IVIS imaging was performed twice weekly (N = 10, **p = 0.001, ****p < 0.0001, two-way ANOVA with multiple comparisons). The data in (b) are presented as mean values ± SD. c Survival curve (N = 10, p < 0.0001, Log-rank test). d Peripheral blood, spleen, and bone marrow was collected from mice on days 39–45 post tumor injection. Single cell suspensions were stained for GRP78, hCD3, and hCD19 and analyzed by flow cytometry to determine the presence of cell surface GRP78+ MOLM13 cells as well as CAR T cells; representative dot plots are shown. Source data are provided as a Source data file.

Back to article page